A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma

Immunotherapy targeting immune checkpoint molecules, programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1), using therapeutic antibodies has been widely used for some human malignancies in the last 5 years. A costimulatory receptor, PD-1, is expressed on T cells and suppresses effector functions wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Maekawa, Naoya, Konnai, Satoru, Takagi, Satoshi, Kagawa, Yumiko, Okagawa, Tomohiro, Nishimori, Asami, Ikebuchi, Ryoyo, Izumi, Yusuke, Deguchi, Tatsuya, Nakajima, Chie, Kato, Yukinari, Yamamoto, Keiichi, Uemura, Hidetoshi, Suzuki, Yasuhiko, Murata, Shiro, Ohashi, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567082/
https://www.ncbi.nlm.nih.gov/pubmed/28827658
http://dx.doi.org/10.1038/s41598-017-09444-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567082/
https://www.ncbi.nlm.nih.gov/pubmed/28827658
http://dx.doi.org/10.1038/s41598-017-09444-2

Ejemplares similares